News

Sales of Merck’s Keytruda (pembrolizumab) are expected to increase, after FDA approved the drug for first-line treatment of melanoma.

The Association for Community Affiliated Plans recently convened 13 plans to take on together the issue of prescription drug abuse.

FDA approved insulin glargine injection (Basaglar, Eli Lilly) to improve glycemic control in patients with diabetes mellitus.

In this opinion piece, members of the Council for Affordable Health Coverage call for support for the Small Business Healthcare Relief Act.

The role of insurance chief operating officer role has expanded greatly in recent years, with responsibilities becoming more strategic and aligned with those of the CEO.

Better management on several fronts should be able to reduce a hospital’s readmissions, but it requires commitment and attention to detail.

Humana’s Medicare Advantage members show better quality, healthier outcomes and lower costs through value-based models.

Four new drugs and a biosimilar should be on your radar.

Pete Mulliner, an IPF patient and ambassador for the Pulmonary Fibrosis Foundation, discusses how he believes physicians should treat patients who have been recently diagnosed with IPF.

When it comes to managing rheumatoid arthritis drugs, cost comes in various sizes and shapes.

What Managed Healthcare Executive content was most popular this year? Find out here.

We asked the Managed Healthcare Executive editorial advisory board to identify the top healthcare challenge in 2015. Here's what they said.

FDA approved Bridion (sugammadex) injection today – after a long wait by Merck & Co. – to reverse the effects of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide, used during certain types of surgery.

Valeant Pharmaceuticals just entered into a new fulfillment agreement with Walgreens and says it will reduce prices of its branded prescription-based dermatological and ophthalmological products such as Jublia by 10 percent.

Federal antitrust officials are determining how, and if, transactions will move forward. Here's a roadmap of what's ahead in 2016.

Here are four critical considerations that are integral to successful implementation of a value-based payment model.

FDA granted accelerated approval to Alecensa (alectinib) for the treatment of people with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.

Hospital stays were shorter for patients treated with Xarelto (rivaroxaban) in a new study, compared to those receiving standard anticoagulants.

We asked four experts what managed healthcare executives need to know about the mental health coverage requirements.

Several studies have demonstrated that telemedicine programs of different types can yield the same or better results than more traditional diabetes interventions.

How can plans and providers turn the dial up on member engagement? We asked three experts to weigh in.

Wellstat Therapeutics Corporation said that its Vistogard, just approved by FDA as the first and only antidote for emergency treatment of adult and pediatric patients following an overdose of the chemotherapy, will be available on the U.S. market soon.

Boehringer Ingelheim recently began a clinical trial to assess the safety and tolerability of adding on pirfenidone to Ofev (nintedanib) for idiopathic pulmonary fibrosis patients.

FDA is warning about ketoacidosis and urinary tract infections associated with the relatively new class of type 2 diabetes medicines called sodium-glucose cotransporter-2 (SGLT2) inhibitors such as Invokana and Jardiance.

Population health management, one of the most pressing priorities for executives today, requires careful planning and strategy. Here are some tips.

FDA has approved recombinant von Willebrand factor (Vonvendi, Baxalta) for use in adults who have von Willebrand disease.

FDA has approved methylphenidate hydrochloride (QuilliChew ER, Pfizer) extended-release chewable tablets for the treatment of ADHD in children.

Genetically engineered chickens were needed to produce Kanuma (sebelipase alfa), newly approved by FDA to treat lysosomal acid lipase deficiency (LAL-D), a genetic and progressive ultra-rare metabolic disease in which patients suffer multi-organ damage and premature death.